Sunshine Biopharma Inc. reported a net loss of $4.03 million for the nine months ended September 30, 2026, compared to a loss of $3.83 million in the prior year period. While revenues decreased slightly to $26.79 million, the company significantly strengthened its cash position to $14.62 million through public offerings and warrant exercises.
Aethlon Medical reported a net loss of $4.17 million for the six months ended September 30, 2026, compared to $3.25 million in the prior year period, driven largely by increased professional fees. The company is currently pursuing a merger with North Immunology, Inc. and has raised capital through common stock issuances to maintain a cash balance of approximately $6.49 million.
Willamette Valley Vineyards reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a $1.7 million loss in the prior year period. Despite a 4.2% increase in net sales to $27.2 million, rising operating expenses and higher cost of sales contributed to a loss applicable to common shareholders of $0.97 per share.
BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.
For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.
American Battery Technology Company reported a net loss of $14.6 million for the quarter ended September 30, 2026, compared to a $10.3 million loss in the prior year. While revenue increased to $1.7 million, the company faced a gross loss of $3.6 million and significantly higher operating expenses driven by general, administrative, and R&D costs.
Ensysce Biosciences reported a significant net loss of $88.2 million for the nine months ended September 30, 2026, primarily driven by a $79.9 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity position, ending the period with $29.7 million in cash following multiple preferred stock and PIPE financing transactions.
MediciNova reported a net loss of $7.7 million for the nine months ended September 30, 2026, an improvement from the $9.2 million loss in the prior year period. The company strengthened its liquidity by raising $6.2 million through an at-the-market equity offering, ending the quarter with $29.3 million in cash and cash equivalents.
Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.
“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”
Prairie Operating Co. reported its Q3 2026 financial results, highlighted by a 31% sequential revenue increase to $129.5 million and a 21% increase in sales volumes to 26,117 Boe/d. Despite the revenue growth, the company recorded a net loss of $34.0 million while generating $65.3 million in Adjusted EBITDA.
Term
Q3 2026
“Prairie’s third-quarter results demonstrate the strength of our assets and the excellent work our team continues to deliver across our development program. Average daily sales volumes increased 21% from the prior quarter to 2.4 MMboe or 26,117 Boe per day, driving revenue growth of 31% from the prior quarter to $129.5 million. We achieved that growth while reducing lease operating expense per Boe by 17% from the prior quarter, reflecting our continued focus on improving well performance and operating efficiency.”
Greg Patton, Chief Executive Officer
“Prairie generated $65.3 million of Adjusted EBITDA in the third quarter, an increase of 92% from the prior quarter, as sales volumes increased and unit operating costs declined. With Burnett and Castor now producing, our focus is on realizing the cash returns from the capital invested this year and carefully managing the spending required to sustain that production.”
Michael Shelly, Executive Vice President and Chief Financial Officer
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.
Legacy Education Inc. reported financial results for its fiscal first quarter ended September 30, 2026, featuring record student population growth of 5.4% year-over-year to 3,684 students. The company achieved revenue of $20.0 million and net income of $0.9 million while expanding its footprint with a new lease for its first planned campus outside California in Houston, Texas.
Legence Corp. reported significant growth in total assets to $3.83 billion as of September 30, 2026, up from $2.68 billion at year-end 2025, driven by increases in contract assets and intangible assets. The company maintained a dual-class share structure with 108,527,517 total shares outstanding and reported a reduction in its accumulated deficit from $309.9 million to $232.1 million during the period.
Audax Private Credit Fund, LLC reported a net increase in net assets from operations of $25.6 million for the nine months ended September 30, 2026, compared to $15.2 million in the prior year period. Total investments at fair value grew to $1.21 billion, while the fund maintained a net asset value per share of $24.86.
KBS Real Estate Investment Trust III, Inc. reported a net loss of $137.1 million for the nine months ended September 30, 2026, compared to a $59.9 million loss in the prior year period. The increased loss was driven by $80.0 million in real estate impairment charges and a $19.2 million unrealized loss on real estate equity securities.
Planet 13 Holdings reported Q3 2026 revenue of $23.1 million, a 1.0% sequential increase driven by strong growth in Florida. The company significantly reduced its net loss to $6.4 million compared to $44.0 million in the prior year, aided by improved gross margins and the exit from California operations. Management highlighted the upcoming December 10 shareholder vote on its proposed merger with Vireo Growth.
Term
Q3 2026
“Revenue increased for the second consecutive quarter, up 1.0% sequentially, led by a 15.1% quarter-over-quarter increase in Florida, where revenue was 45% higher than in the prior-year quarter. The levers we have been pulling in Florida are showing up in the numbers driven by better flower out of our upgraded cultivation, a fuller product lineup with BHO concentrates now on shelf, and a more productive store network.”
Larry Scheffler, Co-CEO of Planet 13
“We delivered a second consecutive quarter of revenue growth and Adjusted EBITDA improvement, and our focus remains on running the business well and executing a smooth path to closing for our stockholders, employees, patients and customers. With the Form S-4 declared effective on November 2, our stockholders will vote on the proposed merger with Vireo Growth at a special meeting on December 10, 2026.”
Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.
Term
Q3 2026
“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
Robinhood Ventures Fund II reported a net investment loss of $1.87 million for the six months ended September 30, 2026, with total assets growing significantly to $217.1 million following its IPO in August 2026. The fund's net asset value per share decreased from $24.72 to $23.21 during the period, primarily driven by organizational expenses and offering costs.
Ondas Inc. reported a significant revenue increase to $301.4 million for the nine months ended September 30, 2026, compared to $20.6 million in the prior year, primarily driven by acquisition activity. Despite a quarterly net loss of $64.7 million, the company achieved a net income of $206.9 million for the nine-month period, largely due to $583.4 million in other income.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
For the nine months ended September 30, 2026, Xos, Inc. reported revenues of $21.5 million, a significant decrease from $40.8 million in the prior year period. The company incurred a net loss of $19.4 million for the first nine months of 2026, while its cash position decreased to $12.1 million as of September 30, 2026.
Newsmax Inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $15.9 million compared to a net loss of $96.5 million in the prior year period. This improvement was driven by a 27.6% increase in total revenues to $174.8 million and a substantial reduction in general and administrative expenses, which had been inflated in 2025 by one-time corporate matters.
For the nine months ended September 30, 2026, iAnthus reported net revenues of $107.2 million and a net loss of $41.9 million, compared to a net loss of $26.1 million in the prior year period. The company's balance sheet shows a significant shift in debt classification, with $208.7 million in long-term debt moving to current liabilities, contributing to a total shareholders' deficit of $143.5 million.
Nuveen Farmland REIT commenced operations in late 2026, completing its initial closing on September 1, 2026, with $34.7 million in proceeds and acquiring an initial portfolio of two assets. For the nine months ended September 30, 2026, the company reported a net loss of $607,000, primarily driven by general and administrative expenses as it established its investment platform.
Ionic Digital Inc. reported a significant shift in its business model, with digital infrastructure leasing revenue of $131.7 million for the nine months ended September 30, 2026, surpassing its cryptocurrency mining revenue. Despite a net loss of $30.9 million for the nine-month period, the company achieved a net income of $17.4 million in the third quarter, bolstered by a $73.2 million gain on the fair value of cryptocurrency assets.
Vivos Inc. reported a net loss of $2,746,628 for the nine months ended September 30, 2026, compared to a loss of $1,987,503 in the prior year period, driven largely by a $847,628 non-operating loss on share issuances. While revenues increased significantly to $101,368 from $43,627, the company continues to operate with a substantial accumulated deficit of over $91 million.
Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.
Term
Q3 2026
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”
Howard Robin, President and Chief Executive Officer of Nektar
INNOVATE Corp. reported a significant turnaround for the third quarter of 2026, with net income attributable to common stockholders of $15.8 million compared to a net loss of $9.4 million in the prior year. Revenue grew to $495.5 million for the quarter, driven by operations and a $32.9 million gain on the sale of a controlling interest in a subsidiary.
Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.
“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”
Dr. Deborah Birx, Chief Executive Officer
“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”
Innventure, Inc. reported a significant net loss for the nine months ended September 30, 2026, primarily driven by a $323.5 million goodwill impairment charge. While revenue increased to $3.88 million from $1.23 million year-over-year, the company faces substantial liquidity risks and is exploring strategic alternatives for its subsidiaries AeroFlexx and Refinity.